Anacor Reworks Collaboration With GSK For Potential Of Additional LeuRS Antibiotics
This article was originally published in The Pink Sheet Daily
Executive Summary
Six-year deal signed in 2007 may be extended if GSK decides to option additional leucyl-tRNA synthetase candidates discovered by Anacor.
You may also be interested in...
GSK Ends Deal For Anacor’s Antibiotic, Returns Rights
The pharma ended the deal after halting studies on an antibiotic for Gram-negative bacterial infections when some clinical patients showed evidence of microbiological resistance.
Novel Antibiotics At ICAAC Spur Optimism On Resistance Front
While short-term prospects are dim for new antibiotics to treat multi-drug-resistant pathogens – Gram-negative bacteria in particular – research presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy indicates a handful of novel compounds could be ready for prime time in as few as four or five years.
Novel Antibiotics At ICAAC Spur Optimism On Resistance Front
While short-term prospects are dim for new antibiotics to treat multi-drug-resistant pathogens – Gram-negative bacteria in particular – research presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy indicates a handful of novel compounds could be ready for prime time in as few as four or five years.